

Cover Story
Clinical
Imatinib—the pathbreaking cancer drug that gave Philadelphia chromosome-positive chronic myeloid leukemia patients near-normal life expectancies—now stands poised to save even more lives.
Health Equity
By Matthew Bin Han Ong
In Brief


Clinical Roundup


Drugs & Targets
NCI Trials


NCI Trials for November 2023
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- Right-wing provocateur Laura Loomer comes for FDA’s Vinay Prasad
- FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts
- Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER director
His appointment came out of “proximity” to Makary and Bhattacharya - Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out
- Shane Jacobson named CEO of the American Cancer Society, ACS CAN
- Robert Winn: If Medicaid gets massive cuts or goes away, where will these patients get care?